Figure EV5. Mutational signatures analyzed in tumor samples with low or high expression of CEP170.

• A
  For each signature analyzed, the distribution of single base substitution considering the previous and following base is shown. Each signature presents a unique profile of mutations.
• B
  Same as in Fig 5I but for samples at the lower quartile (low) or at the highest (high) of the indicated centriolar subdistal appendages proteins. The central band represents the median, the lower and upper hinges correspond to the first and third quartiles and the upper and lower whiskers extends from the hinge to the largest value no further than 1.5 inter‐quartile range.
• C–N
  Survival data in different cancer types with different CEP170 expressions were collected from the web‐based tool GEPIA. Samples were split in two categories, the ones with an expression above the median (high; red lines) or below the median (low; blue lines). The number of individuals for each category is indicated in the top right corner of each chart. Overall survival of each category in each cancer type were plotted in Kaplan‐Meyer graphs. Statistical significance was calculated using a Log‐rank (Mantel–Cox) test and the P‐values are included. Tumor types: (C) ACC, adrenocortical carcinoma. (D) KICH, kidney chromophobe. (E) MESO, mesothelioma. (F) CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma. (G) KIRP, kidney renal papillary cell carcinoma. (H) SARC, sarcoma. (I) COAD, colon adenocarcinoma. (J) LICH, liver hepatocellular carcinoma. (K) STAD, stomach adenocarcinoma. (L) DLBC, lymphoid neoplasm diffuse large B‐cell lymphoma. (M) LUSC, lung squamous cell carcinoma. (N) THCA, thyroid carcinoma.